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The study aim was to compare the mortality risk of men and women diagnosed with obstructive
sleep apnoea (OSA) and started on treatment with continuous positive airway pressure (CPAP).
From August to December 2003 we reviewed the hospital records of patients who had started
on CPAP for OSA between July 1995 and June 1998. Mortality rates were compared between
men and women. Associations with mortality risk were determined using univariate and mul-
tivariate Cox’s proportional hazards regression.
The sample comprised 292 men and 47 women. Eight percent of the men and 23% of the
women died (pZ 0.003). Univariate analysis showed increased mortality risk was associated
with female sex, greater age when CPAP was started, a pre-treatment minimum nocturnal
oxygen saturation (SpO2) <75%, a higher Charlson comorbidity index score and discontinuation
of CPAP treatment. Female sex remained associated with increased mortality independent of
age, minimum SpO2 and CPAP use, but was not independent of the Charlson score.
Women diagnosed with OSA and treated with CPAP demonstrated a 3.44 greater mortality
risk than men, mostly due to greater comorbidity.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
Individual studies have shown that obstructive sleep
apnoea (OSA) patients of a particular age group, sex, or
treatment group have higher mortality rates than the
general population but they have not reproduced each
other’s findings.1e4 Comparisons of the mortality risk of0) 1480 364173; fax: þ44 (0)
th.nhs.uk (I.E. Smith).
8 Elsevier Ltd. All rights reservedsleep clinic patients with and without sleep disordered
breathing (SDB) have also had varied results.5,6 The propor-
tions of women in these studies have ranged between 0%
and 14% whereas community population studies suggest
that 25%e33% of people with OSA are women.7e11 Women
and men diagnosed with OSA in sleep clinics may have
different characteristics which may result in them having
a different mortality rate, as has been found in some
series.2,3,12
The primary aim of this study was to compare the
mortality risk of men and women diagnosed with obstruc-
tive sleep apnoea and started on treatment with.
1232 E. Morrish et al.continuous positive airway pressure (CPAP) at our sleep
centre. Our secondary aim was to assess whether mortal-
ity risk was associated with severity of OSA, body mass
index (BMI), comorbidity and continuation with
treatment.
Methods
Study subjects
We identified individuals diagnosed with OSA with a noctur-
nal oxygen desaturation index (ODI) 5 who had started
CPAP at Papworth Hospital as National Health Service (NHS)
patients between July 1995 and June 1998. Patients were
referred to the sleep centre by both family and hospital
doctors. Patients whose OSA was associated with a neuro-
muscular disorder, those who had previously been treated
for OSA with CPAP or an alternative device, those who were
initiated on bi-level positive airway pressure (PAP) for
associated ventilatory failure, and those who had partici-
pated in related pharmaceutical trials were excluded from
this study.
Patients were diagnosed according to clinical impression,
overnight pulse oximetry and Epworth Sleepiness Scale (ESS)
score.13 Overnight oximetry was recorded on Datex Ohmeda
3740 oximeters (Louisville, USA) and printed using chart re-
corders. Patients who were strongly suspected of having OSA
but did not demonstrate oxygen desaturations on oximetry
were re-assessed by polysomnography (PSG). If there was
a strong suspicion that a patient had a sleep disorder other
than or in addition to OSA they underwent PSG without prior
overnight oximetry. This small subset of patients was not in-
cluded in the study since the requirement for them to have
a different method of diagnosis may have biased their
outcome.
Consistent with local policy, patients have been mon-
itored at least once a year unless; CPAP treatment was
withdrawn, their care was transferred to another hospital,
they stopped CPAP or failed to attend appointments.
Monitoring comprises an outpatient or inpatient hospital
visit where the patient’s ESS score and weight are
recorded and average nightly CPAP use calculated from
clock readings. Improved compliance is encouraged where
necessary. Overnight oximetry whilst using CPAP was
recorded at follow-up for at least 2 years and the CPAP
level altered if indicated. Oximetry records were printed
on chart recorders and analysed visually until June 2001
and using a digital algorithm (Download, Stowood Scien-
tific, UK) thereafter. Patients who remain excessively
sleepy despite optimum CPAP therapy undergo further
assessments.
Study design
The study protocol was approved by the Huntingdon Local
Research Ethics Committee, Cambridge, UK. The hospital
records of patients who met the criteria outlined above
were reviewed retrospectively. The relative mortality risk
of men and women was calculated and associations de-
termined using univariate and multivariate Cox’s propor-
tional hazards regression.Methods
The hospital records were reviewed between August and
December 2003. One investigator (EM) re-analysed the
oximetry traces to identify mean and minimum oxygen
saturation (SpO2) and calculate the oxygen desaturation in-
dex (ODI, 4%) per hour. Patients were excluded if their
pre-treatment oximetry study was unavailable or the ODI
was less than 5. Data were collected regarding: sex, date
of birth; ESS score, oximetry data at diagnosis; date when
CPAP was started, smoking status at that time, weight
and height as measured on admission or reported by the pa-
tient and history of cardiovascular disease, lung disease and
diabetes, which was then compared to prescribed medica-
tions to minimise the risk of missing comorbid conditions.
BMI was calculated from weight and height. The Charlson
comorbidity index score was calculated by summing scores
assigned to a list of comorbidities according to their rela-
tive association with mortality.14
Between 22 March and 22 April 2004 we determined
whether each patient was alive or dead using the NHS
tracking system, which has a record of deaths accurate to
2 weeks. Subjects were classified as; alive and still using
CPAP, alive but not using CPAP or deceased. For those that
had died it was determined whether they were still using
CPAP under our follow-up at the time of their death.
Death certificates were requested and cause of death
recorded.
Patients still using CPAP at the time their notes were
reviewed or when they died will be referred to as CPAP
users. The latest oximetry results, average nightly CPAP
use, weight and ESS score whilst using CPAP were recorded
for the CPAP users that were still under our care (Papworth
CPAP users). Patients transferred in the course of follow-up
to bi-level PAP were counted with CPAP users.Statistical analysis
Statistical analyses were performed using SPSS computer
software version 12.0 (SPSS Inc, Chicago, IL, USA). Men and
women were compared for variables recorded at diagnosis
and when CPAP was started, for the proportion that had
died and for the proportion that continued to use CPAP. For
Papworth CPAP users the latest treatment follow-up data
were compared to the pre-treatment values and between
men and women. Comparisons were made using Student’s-t,
ManneWhitney U, Chi-square or Wilcoxon Signed Rank tests
as appropriate.
Exploratory analysis was carried out on pre-treatment
continuous variables to see if they approximated a linear
relationship with mortality. Those without a linear relation-
ship were transformed into categorical variables. Univari-
ate Cox’s proportional hazards regression was used to
identify significant associations between mortality and;
sex; pre-treatment ESS score, mean and minimum over-
night SpO2 and ODI; age, BMI, smoking status and Charlson
score when CPAP was started; and whether or not CPAP was
still being used at the time of data collection or time of
death. Variables that showed a significant association
with mortality were entered into multivariate Cox’s propor-
tional hazards regression in a stepwise manner.
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Three hundred and thirty-nine subjects met the inclusion
criteria; 292 (86%) men and 47 (14%) women (ratioZ 6:1).
As of 22 Marche22 April 2004 34 (10%) subjects were known
to have died. The mortality status of one man and one
woman could not be confirmed so their data were censored
from the time they were last known to be alive. The cause
of death was recorded as indeterminate after post mortem
in one patient. The death certificates of two patients were
not available. Proportionally more women had died than
men (23.4% versus 7.9%; pZ 0.003). Most subjects died
due to a circulatory disorder (nZ 19; 55.9%), while 7
(20.6%) died of cancer and 5 (14.7%) of other causes. Uni-
variate regression showed the hazard of death was 3.44
times greater for women than men (95% CI: 1.68e7.08;
pZ 0.001) (Fig. 1).
The variables at diagnosis and at the time of starting
CPAP that were significantly different between men and
women are shown in Table 1. There was a trend for women
to be older than the men when they started CPAP (mean
(SD) age in years: womenZ 54.3 (11.3), menZ 51.4
(10.9); pZ 0.097). Other characteristics of the sample
that were not significantly different between men and
women are shown in Table 2.
The proportions of men and women CPAP users are
shown in Fig. 2. Of the 252 CPAP users, 237 (94%) remained
under our care. There was no significant difference in the
proportions of men and women who were CPAP users (76%
and 62%, respectively) (p> 0.05). A greater proportion of
women than men had been lost to follow-up so it was not
known whether they were using CPAP or not (13% versus
3%; pZ 0.014). Only 5 patients transferred to bi-level PAP
during follow-up, 4 men and 1 woman.
Both men and women Papworth CPAP users (nZ 211 and
26, respectively) had a reduced ESS score and ODI and in-
creased mean and minimum SpO2 at follow-up compared
to baseline (p 0.002 for all) indicating effective treat-
ment in most patients. The women had a significantly
higher ESS score at follow-up compared to the menTime from starting CPAP to status confirmed (years)
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Figure 1 KaplaneMeier survival curve for women and men
who started CPAP based on univariate analysis.(p< 0.001) despite similar compliance and overnight oxi-
metry data. Fewer women than men had a fall from the
pre-treatment ESS at their most recent CPAP follow-up visit
(79% versus 93%; p< 0.05).
Age when CPAP was started was the only continuous
variable with a linear relationship with mortality risk. In
addition to sex the variables that were associated with
mortality in univariate analysis were; age when started
CPAP, pre-treatment minimum overnight SpO2, Charlson score
and whether or not subjects were CPAP users (Table 3).
BMI, ESS score, smoking status, mean SpO2 and ODI were not
associated with mortality.
The effects of sex and age on mortality risk were
modelled and the effect of the stepwise addition of the
other variables from Table 3 was assessed (Table 4). Female
sex was associated with increased mortality risk indepen-
dent of age when CPAP was started, minimum SpO2 on over-
night oximetry before treatment, and whether or not
treatment with CPAP/bi-level PAP was continued (Table 4,
models 1e3). However, when the Charlson score was added
(Table 4, model 4) female sex was no longer associated with
mortality whereas all the other variables remained
significant.Discussion
We have found that the women we diagnosed with OSA and
initiated on treatment with CPAP have a 3.44 times greater
mortality risk than the men. Twenty-three percent of the
women and 8% of the men died. Compared to the men, the
women had significantly greater BMIs, were slightly older
(not statistically different) and had more comorbidity when
they started CPAP but had less severe SDB as measured by
ODI. More women than men were lost to follow-up. Other
factors associated with increased mortality were a minimum
SpO2< 75% on pre-treatment overnight oximetry, increased
age and more comorbidity at start of treatment, and
whether or not CPAP or bi-level PAP was still being used.
Pre-treatment BMI, ESS score, ODI, mean SpO2 and smoking
status were not associated with mortality.
The following study limitations should be considered
when interpreting the results. Firstly the patients included
in this study were given a diagnosis of OSA based on clinical
impression and oximetry results rather than PSG, which has
been generally considered to be the gold standard. None-
theless there is accumulating evidence that when combined
with expert clinical assessment, overnight oximetry is as
effective as PSG in predicting which patients with symp-
toms suggestive of OSA will improve with CPAP treatment in
terms of quality of life.15 There is also evidence to show
that there is no difference in mean oxygen desaturation
or minimum oxygen saturation during sleep between clini-
cal groups of men and women16,17 except when men and
women are matched for BMI and age.16
We were unable to identify patients that were recom-
mended CPAP treatment but refused it. Likewise we did not
include patients who had an oxygen desaturation index
below 5 but were subsequently diagnosed with OSA based
on a later PSG study. This could bias our study population.
However, there is no evidence to suggest that the study is
biased in terms of the ratio of men to women that we
Table 1 Baseline variables that showed a significant difference between men and women (p 0.05)
Variable Men Women p-value
Median (IQR)
ODI (desaturations/hour) 19 (9.3e38) 13 (9e24) 0.018
BMI (kg/m2) 32.2 (28.5e38.0) 37.1 (30.8e42.8) 0.004
Frequency
Previous CVA 1.0% 10.6% 0.002
Diabetes mellitus 6.2% 17.0% 0.017
Charlson scorea,14 78%, 19%, 3% 51%, 28%, 21% <0.001
CVAZ cerebrovascular accident.
a Frequency of scores of 0, 1 and 2. A higher score indicates greater comorbidity.
1234 E. Morrish et al.discharged with CPAP since this was similar to the ratio
of men and women diagnosed with OSA in previous
samples 6,18,19 and in our experience proportionally fewer
women are referred for sleep studies.
Unlike some previous studies of mortality in OSA3,18,19
we were able to identify deaths amongst patients who
had stopped using CPAP giving a true mortality rate of the
men and women in our study sample for comparison. This
may be important since we found that there was a trend
for more women to stop using CPAP and a higher proportion
of women were lost to follow-up so their CPAP use was un-
known. This finding is consistent with the results of another
UK study.20 In our study the patients who no longer used
CPAP had a higher risk of death than those continuing to
use it under regular follow-up. Similarly, two recent studies
found that people who had refused or had stopped using
CPAP had a greater cardiovascular mortality risk than
CPAP users21,22 although one found no increase in overall
mortality risk.21 We do not know if the increased mortality
risk of patients who stop using CPAP is due to their un-
treated OSA. It is possible that their lack of compliance is
an indicator of other behaviours that adversely affect out-
come, in the same way that chronic heart failure patients
who did not comply with placebo medication had a higher
mortality risk than those who complied.23 Regardless of
the reason, mortality studies of OSA patients that exclude
those who are not followed-up miss a sub-population atTable 2 Baseline variables that were not significantly dif-
ferent between men and women (p> 0.05) (whole group
data)
Variable
Median (IQR)
ESS score13 (nZ 314) 16 (13e19)
Mean overnight SpO2 93 (90e95)
Minimum overnight SpO2 76 (67e82)
Prevalence (%)
Current smoker (nZ 333) 28.9
Hypertension 30.7
Ischaemic heart disease 11.2
Chronic obstructive
pulmonary disease
3.5
Atrial fibrillation 3.2
Heart failure 3.2a higher risk, which in our study included relatively more
women than men.
Like all but one22 other published studies of mortality in
OSA patients, our study has limitations related to its retro-
spective nature. For example, the comorbidity data ex-
tracted from hospital notes could be incomplete. Also,
other data that we might choose to collect in a prospective
study are not necessarily available from hospital records.
Of particular interest would be information regarding the
length of time between symptom onset and referral to
the sleep centre and the number of contacts the patients
have had with medical practitioners in this time. Informa-
tion of this type might have helped us to determine
whether the women in our sample had greater comorbidity
because women with SDB are more susceptible to SDB-re-
lated cardiovascular disease24 or because they have
a greater delay in diagnosis that might contribute to an in-
creased level of comorbidity. The women in our sample
were slightly older than the men but we do not know
whether they had OSA for longer before being treated. Pre-
vious research has shown that women with OSA had symp-
toms of SDB for longer than men before being diagnosed25
but a second series found no difference in symptom dura-
tion.26 However, this series included women with more se-
vere breathing disturbance that was matched for apnoea
hypopnoea index with the men whereas in our sample and
other clinical samples the women have less breathing dis-
turbance than the men.270%
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Figure 2 Proportions of men and women using CPAP at Pap-
worth Hospital or an alternative hospital, or using bi-level PAP
at time of data collection or time of death.
Table 3 Univariate Cox’s Proportional Hazards regression:
variables other than sex that showed significant associations
with mortality
Variable n Hazard ratio (95% CI)
Age (single years) 339 1.08z (1.04e1.11)
Minimum overnight SpO2 (%)
75 187 1
<75 152 3.19y (1.52e6.67)
Charlson score14
0 252 1
1 68 3.63y (1.54e8.55)
2 19 20.97z (9.37e46.94)
CPAP still issued
Yes (or bi-level PAP) 257 1
No or unknown 82 2.65y (1.35e5.22)
y p 0.01; z p 0.001.
Why does gender influence survival in OSA? 1235It should be noted that the greater comorbidity recorded
in our female patients might have caused pre-selection of
the women that we see in the sleep clinic. These patients
are likely to have had multiple contacts with medical
services due to comorbidities, increasing the likelihood of
them reporting their symptoms and/or their symptoms
being recognised and subsequent referral to a sleep centre.
It has been shown previously that women have more
healthcare utilisation in the 5 years prior to a diagnosis of
OSA than do men.28 The ratio of men to women that we dis-
charged with CPAP treatment was 6e1. The ratio of men to
women with OSA estimated from community studies is 2 or
3e1.7e10 Thus our results can only reflect the mortality of
men and women diagnosed and treated for OSA not the
mortality of all people with OSA.
Of the individual comorbidities we recorded, a history of
heart failure or cerebrovascular accident (CVA) seemed to
have the strongest associations with mortality (data notTable 4 Multivariate Cox’s Proportional Hazards Regression. Th
95% confidence intervals in brackets
Variable Model 1 Model 2
Sex
Men 1 1
Women 2.87y (1.39e5.94) 2.40* (1.1
Age (single year) 1.07z (1.04e1.11) 1.07z (1.0
Minimum overnight SpO2 (%)
75 1
<75 3.28y (1.5
CPAP still issued
Yes (or bi-level PAP)
No or unknown
Charlson score14
0
1
2
*p 0.05; y p 0.01; z p 0.001.shown) but due to their low prevalence and interactions
between comorbidities reliable statistical analysis was not
possible. Other studies have found associations with mor-
tality and heart failure,29 hypertension,1 heart disease,1 di-
abetes mellitus29 and chronic obstructive pulmonary
disease (COPD).3,4,29 The lack of association between
COPD and mortality in this study may be due to the much
lower prevalence of COPD in our population. A large propor-
tion of patients referred to our care with OSA and COPD
have been treated with bi-level ventilation rather than
CPAP and were therefore not included in this study.
Use of the Charlson comorbidity index allowed us to
perform statistical analysis on our population. The index
was initially designed to predict outcomes for patients with
cancer but has been used in other conditions including
heart disease and stroke.30 Increasing Charlson scores were
associated with increased mortality risk in a previous study
of OSA patients.12 We also found a higher Charlson score
had a strong association with increased mortality risk and
when it was entered into the multiple regression model
sex was no longer independently associated with mortality
risk. This indicates that the greater comorbidity recorded in
women explains most of the difference between the mor-
tality risk for women and men. In a previous study the in-
vestigators excluded subjects if they had low life
expectancies due to comorbidity, which may explain their
finding of a greater mortality risk for men compared to
women.3
We have found that women started on CPAP to treat OSA
have an increased mortality risk compared to men. It is
likely that this in part is due to the women being older when
they started treatment and being less likely to continue
with CPAP treatment but mostly by their greater comor-
bidity. It may be that it is the contact with medical services
for these comorbidities that eventually results in referral of
women to a sleep centre. Our results demonstrate the
importance of including all patients started on treatment in
the analysis rather than excluding patients with certain
comorbidities or those who discontinue CPAP as in previouse values in the table represent the hazard of death with the
Model 3 Model 4
1 1
3e5.08) 2.24* (1.06e4.72) 0.95 (0.39e2.29)
4e1.10) 1.07z (1.04e1.10) 1.06z (1.03e1.10)
1 1
6e6.92) 3.44z (1.62e7.32) 2.57* (1.19e5.59)
1 1
2.50y (1.26e4.94) 2.10* (1.04e4.23)
1
2.93* (1.24e6.94)
11.14z (4.34e28.63)
1236 E. Morrish et al.studies. More studies are required to assess the time lapsed
between patients developing OSA and being diagnosed and
treated and the reasons for this delay. Prospective studies
may clarify whether OSA patients with greater comorbidity
are those who have had untreated OSA for longer or are
more likely to be diagnosed with OSA because more health
care professionals have assessed them.
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